Shexiang-Wulong Pills Attenuate Rheumatoid Arthritis by Alleviating Inflammation in a Mouse Model of Collagen-Induced Arthritis

Abstract EN

Shexiang-Wulong Pill (SWP) is derived from “Moschus Yuan,” first formulated during the Song Dynasty for the treatment of joint pain.

The aim of this study was to evaluate the therapeutic effect of SWP in a mouse model of collagen-induced arthritis (CIA).

Forty-five DBA/1 mice were randomly divided into control group, model group, and SWP-treated group.

SWP was administered by oral gavage for 22 days after the booster immunization.

The clinical arthritic scores and joint histopathology, including synovial hyperplasia and hypoxic regions, cartilage erosion, and bone destruction, were evaluated.

Microcomputed tomography (micro-CT) was used to assess microstructural changes in the bone.

Serum levels of TNF-a, IL-6, and IFN-γ were measured by enzyme-linked immunosorbent assay (ELISA).

The results showed a statistically significant improvement in joint pathological changes in the SWP-treated group.

Imaging assessment confirmed that SWP protected the bone tissue from CIA-induced erosion and increased the bone density.

In addition, the serum levels of TNF-a, IL-6, and IFN-γ in SWP-treated mice were significantly lower than those in the model group (P<0.05).

Taken together, Shexiang-Wulong Pill can effectively alleviate joint swelling in CIA mice, inhibit synovial tissue hyperplasia, reduce inflammatory cell infiltration, and delay bone destruction.

These results indicate that Shexiang-Wulong Pills could be an efficient medication for the treatment of RA.